Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

AbbVie (ABBV) Earnings Preview: Buy or Sell Opportunities

While AbbVie (ABBV) saw a decrease in net revenues and EPS in the last reported quarter, it raised its 2023 adjusted EPS guidance range. With the company gearing up to report fourth-quarter 2023 results tomorrow, is the stock worth buying today? Keep reading.

StockNews.com

AbbVie Stock Moves With Rising Relative Strength, Still Room To Grow

AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

A new test could save arthritis patients time, money and pain. But will it be used?

Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

Are These 3 Pharma Stocks Smart Buys for Bullish Investors?

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

StockNews.com

Stock market today: Asian shares are mostly higher ahead of a key US jobs report

Asian shares are mostly higher ahead of a U.S. jobs report after Wall Street rose Thursday to snap its first three-day losing streak since Halloween

The Independent UK

What it really takes to be a great place to work

There’s no one-size-fits-all model, but it can be done at virtually any organization.

Fortune

Analyzing December Profit Potential for the Top 4 Pharma Stocks

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Broader Market Settles Higher on Improved Soft-Landing Prospects

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.25%. Stocks on Thursday settled mixed, with the Dow Jones...

Barchart

Stocks Mixed as Higher Bond Yields Weigh on Tech Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.84%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.77%. Stocks this morning are mixed, with the Dow Jones...

Barchart

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

AbbVie agreed to buy ImmunoGen for $10.1 billion in cash, offering a rich premium for the maker of ovarian cancer treatment drug Elahere.

Investors Business Daily

3 Defensive Dividend Stocks to Protect Your Portfolio

Dividend-paying stocks are having a tough year, but there are still some top-rated income picks worth buying at current levels. Here's a look at three dividend stocks that can actually help defend your portfolio from market volatility.

Barchart

Can Pfizer (PFE) and AbbVie (ABBV) Cure Your Portfolio's Ailments?

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Amid this, let’s analyze the fundamentals of AbbVie (ABBV) and Pfizer (PFE) to determine whether these stocks are worth buying now.

StockNews.com

AbbVie Stock Dives As Cosmetic Sales Mar Its Third-Quarter Beat And Guidance Boost

AbbVie posted a nearly perfect third-quarter beat Friday, but AbbVie stock skidded on light aesthetics sales and as Humira sales fell.

Investors Business Daily

Drugmaker AbbVie Stock Sees Improved Relative Price Strength

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

AbbVie Stock Moves Higher With Rising Relative Strength

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

Investors Business Daily

AbbVie Stock Shows Rising Relative Strength Rating

AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke

Revance is reversing course to stay competitive with AbbVie's aesthetics drug, Botox — and RVNC stock crashed Tuesday in response.

StockNews.com

Top 3 Pharma Stocks to Boost Your Portfolio

As the global population ages and faces the increasing toll of chronic diseases, the pharmaceutical industry is expected to step up to meet people’s healthcare needs. Against this backdrop, pharma companies like Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) could boost your portfolio. Read on….

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Building Wealth with Spinoffs: How Adding These Gems Can Transform Your Portfolio

Spinoffs are value creating investment opportunities. You should be looking at them

Investors Business Daily

The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

Salon

Big Pharma’s playbook for expensive meds

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

Investors Business Daily

How Revance Is Taking A Page Out Of AbbVie's Botox Playbook

Revance's frown-line injection, Daxxify, gained U.S. approval on Monday to treat an involuntary movement disorder, and RVNC stock rose.

StockNews.com

Are Pfizer (PFE) and AbbVie (ABBV) Good Value Buys for August?

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

Zenger

AbbVie’s Underperformance, Deere’s Catch-Up Potential, And Pioneer’s Earnings Awaited

AbbVie's underperformance, Jim Lebenthal sees Deere as a catch-up trade, and analysts await Pioneer's earnings report.

Barchart

3 High-Paying Unusually Active Put Options to Sell for Extra Cash This Weekend

It’s the last day of the trading week, so investors are looking for extra spending money for the weekend ahead. Here are three unusually active put options to sell: high-paying and worthwhile long-term holds.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.